Luis García‐Ortiz

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 600 citations · Full text

Metabolic Syndrome, Diabetes Management, Urology +10

Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study

Rafel Ramos, Marc Comas‐Cufí, Ruth Martí‐Lluch et al. · BMJ · 2018 · 220 citations · Full text

Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients

Ana M. Blázquez‐Medela, Luis García‐Ortiz, Manuel A. Gómez‐Marcos et al. · BMC Medicine · 2010 · 119 citations · Full text

Effectiveness of A Multifactorial Intervention in Increasing Adherence to the Mediterranean Diet among Patients with Diabetes Mellitus Type 2: A Controlled and Randomized Study (EMID Study)

Rosario Alonso‐Domínguez, Luis García‐Ortiz, María C. Patino‐Alonso et al. · Nutrients · 2019 · 99 citations · Full text